Replies to post #1299 on Dendreon Corp fka DNDNQ

[p3analyze]

Thanks Ocyan for the analysis.

My take on the prostate cancer specific death analysis is that it serves the purpose of assuring FDA that when non-prostate cancer death is excluded, the survival advantage remains. An HR of 50% is a pleasant surprise.

[io_io]

<<<This p-value means that the chance that Provenge is a fluke is 1 in 500!>>>


CyanBlue

Good morning on a great day - would you happen to know if this was a one-sided or two-sided p-value ?

If it happened to be 2-sided (more common, except against placebo), then that 1-in-500 improves to 1-in-1,000.

Either way worth an extra 3-4 votes at the Panel.

[DrBengtP]

Ocyan: Could you please enlighten me on:
- who is Dr. Petrylak and
- when (and why) is he going to give presentation

Do you happen to have an indication of when the 9902A results are likely to be made public in more detail (such as cause specific mortality).

TIA

Br.
Bengt